Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

2.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
3.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
4.

Mechanisms of Resistance to Immune Checkpoint Blockade.

Liu D, Jenkins RW, Sullivan RJ.

Am J Clin Dermatol. 2019 Feb;20(1):41-54. doi: 10.1007/s40257-018-0389-y. Review.

PMID:
30259383
5.

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.

Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, Cañadas I, Thai TC, Kitajima S, Chiono V, Paweletz CP, Barbie DA, Kamm RD, Jenkins RW.

Lab Chip. 2018 Oct 9;18(20):3129-3143. doi: 10.1039/c8lc00322j.

PMID:
30183789
6.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

7.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutiérrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK.

Clin Cancer Res. 2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26.

8.

Mechanisms of resistance to immune checkpoint inhibitors.

Jenkins RW, Barbie DA, Flaherty KT.

Br J Cancer. 2018 Jan;118(1):9-16. doi: 10.1038/bjc.2017.434. Epub 2018 Jan 2. Review.

9.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

10.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

11.

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer.

Jenkins RW, Thummalapalli R, Carter J, Cañadas I, Barbie DA.

Annu Rev Med. 2018 Jan 29;69:333-347. doi: 10.1146/annurev-med-060116-022926. Epub 2017 Nov 3. Review.

PMID:
29099676
12.

Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.

Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, Damato E, Aguirre AJ, Liang J, Liberzon A, Alexe G, Doench J, Ghandi M, Vazquez F, Weir BA, Tsherniak A, Subramanian A, Meneses-Cime K, Park J, Clemons P, Garraway LA, Thomas D, Boehm JS, Barbie DA, Hahn WC, Mesirov JP, Tamayo P.

Cell Syst. 2017 Aug 23;5(2):105-118.e9. doi: 10.1016/j.cels.2017.08.002.

13.

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.

Jenkins RW, Barbie DA.

Cancer Discov. 2017 Aug;7(8):799-801. doi: 10.1158/2159-8290.CD-17-0607.

14.

Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase.

Bai A, Mao C, Jenkins RW, Szulc ZM, Bielawska A, Hannun YA.

PLoS One. 2017 Jun 14;12(6):e0177805. doi: 10.1371/journal.pone.0177805. eCollection 2017.

15.

Synthesis of Acetone-Derived C6 , C9 , and C12 Carbon Scaffolds for Chemical and Fuel Applications.

Moore CM, Jenkins RW, Janicke MT, Kubic WL Jr, Polikarpov E, Semelsberger TA, Sutton AD.

ChemSusChem. 2016 Dec 20;9(24):3382-3386. doi: 10.1002/cssc.201600936. Epub 2016 Dec 9.

PMID:
27933751
16.

The Effect of Functional Groups in Bio-Derived Fuel Candidates.

Jenkins RW, Moore CM, Semelsberger TA, Chuck CJ, Gordon JC, Sutton AD.

ChemSusChem. 2016 May 10;9(9):922-31. doi: 10.1002/cssc.201600159. Epub 2016 Apr 21.

PMID:
27099975
17.

Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.

Yang S, Imamura Y, Jenkins RW, Cañadas I, Kitajima S, Aref A, Brannon A, Oki E, Castoreno A, Zhu Z, Thai T, Reibel J, Qian Z, Ogino S, Wong KK, Baba H, Kimmelman AC, Pasca Di Magliano M, Barbie DA.

Cancer Immunol Res. 2016 Jun;4(6):520-30. doi: 10.1158/2326-6066.CIR-15-0235. Epub 2016 Apr 11.

18.

NRAS mutant melanoma: an overview for the clinician for melanoma management.

Jenkins RW, Sullivan RJ.

Melanoma Manag. 2016 Mar;3(1):47-59. doi: 10.2217/mmt.15.40. Epub 2016 Feb 17. Review.

19.

Lack of Acid Sphingomyelinase Induces Age-Related Retinal Degeneration.

Wu BX, Fan J, Boyer NP, Jenkins RW, Koutalos Y, Hannun YA, Crosson CE.

PLoS One. 2015 Jul 13;10(7):e0133032. doi: 10.1371/journal.pone.0133032. eCollection 2015.

20.

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA.

Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7. No abstract available.

21.

Renewable biofuel additives from the ozonolysis of lignin.

Chuck CJ, Parker HJ, Jenkins RW, Donnelly J.

Bioresour Technol. 2013 Sep;143:549-54. doi: 10.1016/j.biortech.2013.06.048. Epub 2013 Jun 22.

PMID:
23831897
22.

Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis.

Jenkins RW, Clarke CJ, Lucas JT Jr, Shabbir M, Wu BX, Simbari F, Mueller J, Hannun YA, Lazarchick J, Shirai K.

Am J Hematol. 2013 Nov;88(11):E265-72. doi: 10.1002/ajh.23535. Epub 2013 Aug 30.

23.

Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease.

Snider AJ, Wu BX, Jenkins RW, Sticca JA, Kawamori T, Hannun YA, Obeid LM.

Prostaglandins Other Lipid Mediat. 2012 Dec;99(3-4):124-30. doi: 10.1016/j.prostaglandins.2012.08.003. Epub 2012 Aug 31.

24.

Numb chin syndrome in acute myeloid leukemia.

Jenkins RW, McDonald K, Greenberg CS.

Am J Med Sci. 2012 Sep;344(3):237-40. doi: 10.1097/MAJ.0b013e318256041f.

PMID:
22739562
25.

Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain.

Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, Beyer J, Kells AP, Bringas J, Sebastian WS, Richardson RM, Rosenbluth KH, Hannun YA, Bankiewicz KS, Forsayeth J.

Hum Gene Ther. 2012 Aug;23(8):891-902. doi: 10.1089/hum.2012.052.

26.

Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release.

Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM.

Immunology. 2012 May;136(1):30-45. doi: 10.1111/j.1365-2567.2012.03552.x.

27.

Defining a role for sphingosine kinase 1 in p53-dependent tumors.

Heffernan-Stroud LA, Helke KL, Jenkins RW, De Costa AM, Hannun YA, Obeid LM.

Oncogene. 2012 Mar 1;31(9):1166-75. doi: 10.1038/onc.2011.302. Epub 2011 Jul 18.

28.

Accumulation of long-chain glycosphingolipids during aging is prevented by caloric restriction.

Hernández-Corbacho MJ, Jenkins RW, Clarke CJ, Hannun YA, Obeid LM, Snider AJ, Siskind LJ.

PLoS One. 2011;6(6):e20411. doi: 10.1371/journal.pone.0020411. Epub 2011 Jun 8.

29.

Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Canals D, Perry DM, Jenkins RW, Hannun YA.

Br J Pharmacol. 2011 Jun;163(4):694-712. doi: 10.1111/j.1476-5381.2011.01279.x. Review.

30.

Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase.

Clarke CJ, Mediwala K, Jenkins RW, Sutton CA, Tholanikunnel BG, Hannun YA.

J Biol Chem. 2011 Jun 17;286(24):21565-76. doi: 10.1074/jbc.M110.193375. Epub 2011 May 2.

31.

Ceramide synthase-dependent ceramide generation and programmed cell death: involvement of salvage pathway in regulating postmitochondrial events.

Mullen TD, Jenkins RW, Clarke CJ, Bielawski J, Hannun YA, Obeid LM.

J Biol Chem. 2011 May 6;286(18):15929-42. doi: 10.1074/jbc.M111.230870. Epub 2011 Mar 9.

32.

Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.

Jenkins RW, Clarke CJ, Canals D, Snider AJ, Gault CR, Heffernan-Stroud L, Wu BX, Simbari F, Roddy P, Kitatani K, Obeid LM, Hannun YA.

J Biol Chem. 2011 Apr 15;286(15):13292-303. doi: 10.1074/jbc.M110.163378. Epub 2011 Feb 18.

33.

A novel mechanism of lysosomal acid sphingomyelinase maturation: requirement for carboxyl-terminal proteolytic processing.

Jenkins RW, Idkowiak-Baldys J, Simbari F, Canals D, Roddy P, Riner CD, Clarke CJ, Hannun YA.

J Biol Chem. 2011 Feb 4;286(5):3777-88. doi: 10.1074/jbc.M110.155234. Epub 2010 Nov 22.

34.

Selective knockdown of ceramide synthases reveals complex interregulation of sphingolipid metabolism.

Mullen TD, Spassieva S, Jenkins RW, Kitatani K, Bielawski J, Hannun YA, Obeid LM.

J Lipid Res. 2011 Jan;52(1):68-77. doi: 10.1194/jlr.M009142. Epub 2010 Oct 11.

35.

Regulated secretion of acid sphingomyelinase: implications for selectivity of ceramide formation.

Jenkins RW, Canals D, Idkowiak-Baldys J, Simbari F, Roddy P, Perry DM, Kitatani K, Luberto C, Hannun YA.

J Biol Chem. 2010 Nov 12;285(46):35706-18. doi: 10.1074/jbc.M110.125609. Epub 2010 Aug 31.

36.

Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane.

Canals D, Jenkins RW, Roddy P, Hernández-Corbacho MJ, Obeid LM, Hannun YA.

J Biol Chem. 2010 Oct 15;285(42):32476-85. doi: 10.1074/jbc.M110.141028. Epub 2010 Aug 2.

37.

Could ESC (Electronic Stability Control) change the way we drive?

Rudin-Brown CM, Jenkins RW, Whitehead T, Burns PC.

Traffic Inj Prev. 2009 Aug;10(4):340-7. doi: 10.1080/15389580903043446.

PMID:
19593710
38.

Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Jenkins RW, Canals D, Hannun YA.

Cell Signal. 2009 Jun;21(6):836-46. Review.

39.

Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation.

Kitatani K, Sheldon K, Rajagopalan V, Anelli V, Jenkins RW, Sun Y, Grabowski GA, Obeid LM, Hannun YA.

J Biol Chem. 2009 May 8;284(19):12972-8. doi: 10.1074/jbc.M802790200. Epub 2009 Mar 11.

40.

Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid.

Kitatani K, Sheldon K, Anelli V, Jenkins RW, Sun Y, Grabowski GA, Obeid LM, Hannun YA.

J Biol Chem. 2009 May 8;284(19):12979-88. doi: 10.1074/jbc.M809500200. Epub 2009 Mar 11.

41.

Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis.

Yu H, Zeidan YH, Wu BX, Jenkins RW, Flotte TR, Hannun YA, Virella-Lowell I.

Am J Respir Cell Mol Biol. 2009 Sep;41(3):367-75. doi: 10.1165/rcmb.2008-0295OC. Epub 2009 Jan 23.

42.

Molecular targeting of acid ceramidase: implications to cancer therapy.

Zeidan YH, Jenkins RW, Korman JB, Liu X, Obeid LM, Norris JS, Hannun YA.

Curr Drug Targets. 2008 Aug;9(8):653-61. Review.

43.

Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.

Zeidan YH, Jenkins RW, Hannun YA.

J Cell Biol. 2008 Apr 21;181(2):335-50. doi: 10.1083/jcb.200705060.

44.

A novel role for protein kinase Cdelta-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury.

Zeidan YH, Wu BX, Jenkins RW, Obeid LM, Hannun YA.

FASEB J. 2008 Jan;22(1):183-93. Epub 2007 Aug 13.

PMID:
17698617
45.

Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK.

Kitatani K, Idkowiak-Baldys J, Bielawski J, Taha TA, Jenkins RW, Senkal CE, Ogretmen B, Obeid LM, Hannun YA.

J Biol Chem. 2006 Dec 1;281(48):36793-802. Epub 2006 Oct 9.

46.

Pneumonia decision making.

Jenkins RW.

J Gen Intern Med. 1993 Feb;8(2):110-1. No abstract available.

PMID:
8441073
47.

Depressed or just sick?

Jenkins RW.

Arch Intern Med. 1990 Jun;150(6):1349-50. No abstract available.

PMID:
2393437
48.

The incidence and implications of chest radiographic abnormalities following orthotopic liver transplantation.

Costello P, Williams CR, Jenkins RW, Jensen WA, Rose RM.

Can Assoc Radiol J. 1987 Jun;38(2):90-5.

PMID:
2954985
49.

Exogenous vs endogenous transfer of nicotine during smoking.

Jenkins RW Jr, Comes RA.

Int J Appl Radiat Isot. 1976 May-Jun;27(5-6):323-4. No abstract available.

PMID:
955732
50.

A sampling device for septum-sealed blood containers.

Isaacs MD, Dunnett N, Nicholson DJ, Jenkins RW.

Ann Clin Biochem. 1975 Sep;12(5):212-4.

PMID:
15637906

Supplemental Content

Loading ...
Support Center